 |
市場調查報告書
商品編碼
2138164
原發性高草酸尿症：新型療法、未滿足的需求和TPP洞察報告，2026年Primary Hyperoxaluria - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026 |
||||||
市場概覽
- 預計到 2025 年，西班牙原發性高草酸尿症市場規模將達到 1,000 萬美元，到 2035 年將達到 2,200 萬美元。
- 推動市場成長的因素如下：
- RNA標靶療法和疾病修正治療。
- 提高基因檢測的準確性，達到早期診斷
- 未來的進展取決於能夠有效抑制草酸鹽生成並改善長期腎功能結果的治療方法。
原發性高草酸尿症：新興療法和TPP的見解
Thelansis 發布的《原發性高草酸尿症：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026》對該適應症的關鍵新興療法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。
原發性草酸尿症概述
原發性高草酸尿症 (PH) 是一種罕見的遺傳性疾病，會影響肝臟的乙醛酸代謝，導致反覆出現草酸鈣結石、腎鈣質沉著症、慢性腎臟病以及因草酸鹽過量引起的全身性草酸中毒。 PH1、PH2 和 PH3 的嚴重程度各不相同，其中 PH1 尤其與較高的腎衰竭風險有關。治療方案包括增加液體攝取量、鹼化尿液、結石管理、晚期進行透析或腎臟移植。目前的治療趨勢正轉向標靶RNA干擾(RNAi)。 Lumasiran 是一種針對乙醛酸氧化酶的 RNAi 療法，已獲得 FDA 批准用於治療兒童和成人 PH1 患者，以降低尿液和血漿中的草酸鹽水平。 Nedosiran 是一種針對肝臟乳酸脫氫酵素A 的 RNAi 療法，已獲得 FDA 批准用於治療 9 歲及以上腎功能相對正常的 PH1 患者。長期追蹤研究證實草酸鹽水平持續降低，但減少基材和基因療法仍處於研究階段。這些療法或許能夠更長時間地保護腎功能。
主要亮點
- 根據預測，德國原發性高草酸尿症 (PH) 的確診病例數將從 2025 年的 168 例增加到 2035 年的 171 例。
- 原發性高草酸尿症是一種罕見的遺傳性代謝紊亂，其特徵是草酸鹽過度生成，導致反覆腎結石和進行性性腎損傷。
- 診斷延誤會導致不可逆的腎功能障礙和全身性併發症。
- 目前仍有大量未被滿足的治療需求，即能夠阻止疾病進展和維持腎功能的治療方法。
透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：
- 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步豐富了調查結果。
- 調查問卷將根據客戶的要求進行客製化。
交付成果格式：
- PowerPoint簡報
- MS Excel
主要問題
- 詳細的競爭格局趨勢
- 管道分析
- 符合新興療法條件的患者
- 大公司
- 主要作用機制
- 發布日期等的預測
- 臨床試驗現況分析
- 目標患者群
- 試驗終點
- 測試設計
- 受試者招募標準等。
- 未滿足的需求和機遇
- 目前主要療法的有效性
- 未滿足需求的關鍵領域
- 主要未滿足需求的市場規模估算
- 目標產品概況
- 屬性和級別
- 醫生開立的處方
- 預期患者佔有率
- 關鍵意見領袖對領先新興療法的見解
- 意識
- 預期用途/處理線
- 以滿足重大未滿足需求的程度
- KOL評論
目標國家
- G8
- 美國
- EU5
- 法國
- 德國
- 義大利
- 西班牙
- 英國
- 日本
- 中國
大公司
- Alnylam Pharmaceuticals
- YolTech Therapeutics Co., Ltd.
- Arbor Biotechnologies
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
目錄
第1章：主要調查結果及分析師說明
- 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。
第2章 競爭情勢
- 目前的治療方法
- 重點
- 診斷和治療過程/演算法
- 主要療法概述及關鍵意見領袖見解
- 新興療法
- 重點
- 診斷和治療過程/演算法
- 領先的新興療法—概述和關鍵意見領袖見解
第3章 產品屬性分析
- 重點
- 科學屬性
- 商業性特性
- 產品定位
第4章：初步調查
- 目前治療狀態
- 主要治療方法與目標患者族群的比較
- 主要特點和優勢
- 未來治療環境
- 當前挑戰
- 未滿足的需求
- 新興療法
- 主要治療方法與目標患者族群的比較
- 主要特點和優勢
- 未來治療前景
- 未滿足的需求和關鍵意見領袖的期望
第5章：未滿足的需求和TPP分析
- 新興療法的主要未滿足需求和未來成就
- TPP分析與KOL預期
第6章 監理與報銷環境
第7章附錄
Primary Hyperoxaluria Emerging Therapy and TPP Insights
Thelansis's "Primary Hyperoxaluria Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Primary Hyperoxaluria Overview
Primary hyperoxaluria (PH) is a rare inherited disorder of hepatic glyoxylate metabolism in which excess oxalate causes recurrent calcium oxalate stones, nephrocalcinosis, chronic kidney disease, and systemic oxalosis. PH1, PH2, and PH3 differ in severity, with PH1 carrying a high risk of kidney failure. Management includes high fluid intake, urine alkalinization, stone management, and dialysis or transplantation in advanced disease. The therapeutic landscape has shifted toward targeted RNA interference. Lumasiran, an RNAi therapy targeting glycolate oxidase, is FDA-approved for pediatric and adult patients with PH1 to lower urinary and plasma oxalate. Nedosiran, targeting hepatic lactate dehydrogenase A, is FDA-approved for PH1 in patients aged 9 years and older with relatively preserved kidney function. Long-term studies support sustained oxalate reduction, while substrate-reduction and gene-based strategies remain investigational. These therapies may preserve kidney function longer.
Key Highlights
- In Germany, diagnosed Primary Hyperoxaluria (PH) cases are projected to increase from 168 in 2025 to 171 by 2035.
- Primary Hyperoxaluria is a rare inherited metabolic disorder characterized by excessive oxalate production, leading to recurrent kidney stones and progressive renal damage.
- Delayed diagnosis can result in irreversible kidney dysfunction and systemic complications.
- Significant unmet need remains for therapies that prevent disease progression and preserve kidney function.
Market Overview
- The Spain Primary Hyperoxaluria market is projected to grow from $10M in 2025 to $22M by 2035.
- Market growth is driven by:
- Increasing adoption of RNA-targeted and disease-modifying therapies
- Improved genetic testing and earlier diagnosis
- Future growth will depend on therapies that effectively reduce oxalate production and improve long-term renal outcomes.
Insights driven by surveys with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
- Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
Countries Covered
- G8
- United States
- EU5
- France
- Germany
- Italy
- Spain
- U.K.
- Japan
- China
Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country
Companies Mentioned
- Alnylam Pharmaceuticals
- YolTech Therapeutics Co., Ltd.
- Arbor Biotechnologies
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Table of Contents
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies - profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies - profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
